Post‑COVID Resurgence of Mycoplasma pneumoniae in French Children: Hospital Burden, Risk Factors for ICU Admission, and Clinical Implications
Posted inCritical Care Infectious Diseases news Pediatrics Public Health Respiratory

Post‑COVID Resurgence of Mycoplasma pneumoniae in French Children: Hospital Burden, Risk Factors for ICU Admission, and Clinical Implications

A nationwide French multicentre cohort (ORIGAMI) documents a substantial 2023–24 paediatric hospitalisation surge from Mycoplasma pneumoniae, identifies older age, asthma, comorbidity and erythema multiforme as ICU risk factors, and highlights stewardship and surveillance priorities.
Recombinant Quadrivalent Influenza Vaccine (RIV4) Shows Non‑Inferior Immunogenicity and Acceptable Safety in 9–17‑Year‑Olds: Results of a Phase 3 Immunobridging Study
Posted inInfectious Diseases news Pediatrics

Recombinant Quadrivalent Influenza Vaccine (RIV4) Shows Non‑Inferior Immunogenicity and Acceptable Safety in 9–17‑Year‑Olds: Results of a Phase 3 Immunobridging Study

A phase 3 immunobridging study found that a single dose of recombinant quadrivalent influenza vaccine (RIV4) induced non‑inferior HAI responses in 9–17‑year‑olds vs 18–49‑year‑olds, with a comparable safety profile and fewer solicited reactions in adolescents.
Once‑Daily Dolutegravir/Lamivudine Fixed‑Dose Tablets Achieve Robust Pediatric Exposures and Reassuring Safety in the D3/PENTA 21 PK Sub‑Study
Posted inHIV/AIDS news Pediatrics

Once‑Daily Dolutegravir/Lamivudine Fixed‑Dose Tablets Achieve Robust Pediatric Exposures and Reassuring Safety in the D3/PENTA 21 PK Sub‑Study

A nested PK and safety sub‑study of D3/PENTA 21 shows once‑daily DTG/3TC dispersible and film‑coated fixed‑dose tablets deliver adequate drug exposures across WHO weight bands in children 2–<15 years, with no drug‑related discontinuations and comparable PK to historical pediatric data.
Real-world data suggest nirsevimab reduces RSV test-positivity up to 12 months but not beyond — cautious interpretation required
Posted inInfectious Diseases news Pediatrics Respiratory

Real-world data suggest nirsevimab reduces RSV test-positivity up to 12 months but not beyond — cautious interpretation required

A multicentre retrospective TriNetX analysis found reduced odds of RSV test-positivity for infants receiving nirsevimab when last dose was within 6–11 months before testing; protection was strongest within 6 months and not evident beyond 12 months. Methodological limits temper causal inference.
Unilateral Pediatric Chronic Otitis Media with Effusion Impairs Binaural Hearing and Raises Tinnitus Risk: Evidence Challenging Conservative Management
Posted innews Otorhinolaryngology Pediatrics

Unilateral Pediatric Chronic Otitis Media with Effusion Impairs Binaural Hearing and Raises Tinnitus Risk: Evidence Challenging Conservative Management

A prospective cross-sectional study finds unilateral chronic otitis media with effusion (COME) in children is associated with poorer spatial release from masking and high tinnitus prevalence, suggesting potential central auditory consequences that may warrant reappraisal of conservative treatment recommendations.
Early Cochlear Implantation Shows Variable but Clinically Relevant Benefits in Children with Single-Sided Deafness: A Western Australian 10‑Year Series
Posted innews Otorhinolaryngology Pediatrics

Early Cochlear Implantation Shows Variable but Clinically Relevant Benefits in Children with Single-Sided Deafness: A Western Australian 10‑Year Series

A retrospective 10‑year series from Perth Children's Hospital reports heterogeneous long‑term outcomes after pediatric cochlear implantation for single‑sided deafness; earlier implantation (within 1 year) was associated with greater likelihood of benefit in speech‑in‑noise and localization.